Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery
1 other identifier
interventional
30
0 countries
N/A
Brief Summary
After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing cardiac surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15). All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department. According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture. Patient data and statistical analyses: Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge. All statistical analyses will be performed after the 30th patient's discharge and data acquisition
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2016
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 27, 2016
CompletedFirst Posted
Study publicly available on registry
April 29, 2016
CompletedStudy Start
First participant enrolled
May 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2017
CompletedApril 29, 2016
April 1, 2016
5 months
April 27, 2016
April 27, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
whole blood viscosity
with 1 hour after the completion of procedure
Secondary Outcomes (6)
PaO2/FiO2 ratio
with 1 hour after the completion of procedure
hematocrit
with 1 hour after the completion of procedure
glucose
with 1 hour after the completion of procedure
osmolarity
with 1 hour after the completion of procedure
urine output
with 1 hour after the completion of procedure
- +1 more secondary outcomes
Study Arms (2)
Intravenous Crystalloid
PLACEBO COMPARATORcrystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Intravenous HES
ACTIVE COMPARATORHES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Interventions
crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Eligibility Criteria
You may qualify if:
- Patients undergoing coiling embolization procedure due to cardiac surgery
- Patients provided a written informed consent.
- Patients with preoperative serum hemoglobin concentration \>13 g/dL (male) and \>12 g/dL (female)
- Patients with PaO2/FiO2 ratio \>150
You may not qualify if:
- Patients with history of anemia, dyspnea, active infection.
- Patients with endocrine disease
- Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-platelet drug, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing cardiac surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 27, 2016
First Posted
April 29, 2016
Study Start
May 1, 2016
Primary Completion
October 1, 2016
Study Completion
January 1, 2017
Last Updated
April 29, 2016
Record last verified: 2016-04
Data Sharing
- IPD Sharing
- Will not share